JP2003532737A - ２位置換プレグナ−１，３，５（１０）−トリエン誘導体およびコラン−１，３，５（１０）−トリエン誘導体およびそれらの生物活性 - Google Patents

２位置換プレグナ−１，３，５（１０）−トリエン誘導体およびコラン−１，３，５（１０）−トリエン誘導体およびそれらの生物活性

Info

Publication number
JP2003532737A
JP2003532737A JP2001582354A JP2001582354A JP2003532737A JP 2003532737 A JP2003532737 A JP 2003532737A JP 2001582354 A JP2001582354 A JP 2001582354A JP 2001582354 A JP2001582354 A JP 2001582354A JP 2003532737 A JP2003532737 A JP 2003532737A
Authority
JP
Japan
Prior art keywords
hydroxy
pregna
methoxy
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001582354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003532737A5 (enExample
Inventor
ロバート・ヘンリー・ヘス
スンダーラ・カテュガム・スリーニヴァーサセティ・セティ
モーリス・マードック・ペチェット
マイクル・ジャイル
Original Assignee
リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド filed Critical リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド
Publication of JP2003532737A publication Critical patent/JP2003532737A/ja
Publication of JP2003532737A5 publication Critical patent/JP2003532737A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001582354A 2000-05-11 2001-05-11 ２位置換プレグナ−１，３，５（１０）−トリエン誘導体およびコラン−１，３，５（１０）−トリエン誘導体およびそれらの生物活性 Pending JP2003532737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20346200P 2000-05-11 2000-05-11
US60/203,462 2000-05-11
PCT/GB2001/002103 WO2001085755A1 (en) 2000-05-11 2001-05-11 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity

Publications (2)

Publication Number Publication Date
JP2003532737A true JP2003532737A (ja) 2003-11-05
JP2003532737A5 JP2003532737A5 (enExample) 2006-01-05

Family

ID=22754111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001582354A Pending JP2003532737A (ja) 2000-05-11 2001-05-11 ２位置換プレグナ−１，３，５（１０）−トリエン誘導体およびコラン−１，３，５（１０）−トリエン誘導体およびそれらの生物活性

Country Status (16)

Country Link
EP (1) EP1287017B1 (enExample)
JP (1) JP2003532737A (enExample)
KR (1) KR100740354B1 (enExample)
CN (1) CN100338088C (enExample)
AT (1) ATE301130T1 (enExample)
AU (1) AU784563B2 (enExample)
CA (1) CA2408751A1 (enExample)
CZ (1) CZ298835B6 (enExample)
DE (1) DE60112438T2 (enExample)
DK (1) DK1287017T3 (enExample)
ES (1) ES2247102T3 (enExample)
IL (2) IL152728A0 (enExample)
NO (1) NO323857B1 (enExample)
NZ (1) NZ523042A (enExample)
WO (1) WO2001085755A1 (enExample)
ZA (1) ZA200209060B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
JP2004537499A (ja) * 2000-11-27 2004-12-16 エントレメッド インコーポレイテッド 抗血管新生薬
WO2002092100A1 (en) * 2001-05-11 2002-11-21 Marsden, John, Christopher 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use
AU2004224053B2 (en) 2003-03-24 2011-06-09 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
AU2004275693A1 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
JPS54112580A (en) * 1978-02-23 1979-09-03 Nec Corp Electroless discharge lamp
JPS54112849A (en) * 1978-02-23 1979-09-04 Mitsubishi Chem Ind Ltd Preparation of steroid derivative
JPS54117455A (en) * 1978-03-02 1979-09-12 Mitsubishi Chem Ind Ltd Novel 19-norsteroid derivative
JPS54117456A (en) * 1978-03-02 1979-09-12 Mitsubishi Chem Ind Ltd Alkoxysteroid derivative
JP2002544137A (ja) * 1999-05-11 2002-12-24 リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド Ｃ１７アルキル側鎖および芳香族ａ環をもつ治療に使用するステロイド化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54112850A (en) * 1978-02-23 1979-09-04 Mitsubishi Chem Ind Ltd Steroid derivative and its preparation
JPS54117454A (en) * 1978-03-02 1979-09-12 Mitsubishi Chem Ind Ltd Acylsteroid derivative
GB9804861D0 (en) * 1998-03-06 1998-04-29 Res Inst Medicine Chem Chemical compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
JPS54112580A (en) * 1978-02-23 1979-09-03 Nec Corp Electroless discharge lamp
JPS54112849A (en) * 1978-02-23 1979-09-04 Mitsubishi Chem Ind Ltd Preparation of steroid derivative
JPS54117455A (en) * 1978-03-02 1979-09-12 Mitsubishi Chem Ind Ltd Novel 19-norsteroid derivative
JPS54117456A (en) * 1978-03-02 1979-09-12 Mitsubishi Chem Ind Ltd Alkoxysteroid derivative
JP2002544137A (ja) * 1999-05-11 2002-12-24 リサーチ・インスティテュート・フォア・メディスン・アンド・ケミストリー・インコーポレイテッド Ｃ１７アルキル側鎖および芳香族ａ環をもつ治療に使用するステロイド化合物

Also Published As

Publication number Publication date
CZ20023719A3 (cs) 2003-04-16
DK1287017T3 (da) 2005-12-05
EP1287017A1 (en) 2003-03-05
NO20025392D0 (no) 2002-11-11
AU5498401A (en) 2001-11-20
HK1053843A1 (en) 2003-11-07
KR20030031899A (ko) 2003-04-23
AU784563B2 (en) 2006-05-04
DE60112438T2 (de) 2006-06-08
NO323857B1 (no) 2007-07-16
CN1444597A (zh) 2003-09-24
CA2408751A1 (en) 2001-11-15
DE60112438D1 (de) 2005-09-08
ES2247102T3 (es) 2006-03-01
NO20025392L (no) 2003-01-09
ZA200209060B (en) 2004-02-09
KR100740354B1 (ko) 2007-07-26
CZ298835B6 (cs) 2008-02-20
EP1287017B1 (en) 2005-08-03
IL152728A0 (en) 2003-06-24
WO2001085755A1 (en) 2001-11-15
IL152728A (en) 2007-02-11
NZ523042A (en) 2004-05-28
CN100338088C (zh) 2007-09-19
ATE301130T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
EP1179005B1 (en) Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
WO2001077139A1 (de) 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
JP2003532737A (ja) ２位置換プレグナ−１，３，５（１０）−トリエン誘導体およびコラン−１，３，５（１０）−トリエン誘導体およびそれらの生物活性
JP2002505336A (ja) コレン酸アミドおよびその医薬組成物
US6967195B2 (en) 2-substituted pregna-1-3,5(10) triene and chola-1,3,5(10) triene derivatives and their biological activity
JP2003534248A (ja) 選択的活性エストロゲンとしての８β−ヒドロカルビル置換エストラトリエン
HK1053843B (en) 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
CA2359218A1 (en) 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
HUP0302020A2 (hu) 2-Szubsztituált pregna-1,3,5,(10)-trién- és kola-1,3,5(10)-trién-származékok, eljárás elżállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
WO2002092100A1 (en) 17-(c(ch3) (ch2) o-3c (r4, r5) n (r6, r7))-substituted 19-nor-pregna-1, 3, 5(10)-triene derivatives and their medical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090811

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511